10x Genomics (TXG) stock has drawn fresh attention after recent trading, with returns up about 37% over the past month and about 53% over the past 3 months from a US$28.84 last close.

That recent surge comes after a much tougher stretch, with the share price posting a 73.53% year to date share price return and a very large 176.91% 1 year total shareholder return, but still sitting on a 50.37% 3 year and 85.17% 5 year total shareholder return decline. This suggests momentum has only recently rebuilt.

If strong recent gains in 10x Genomics have you looking around the sector, this could be a good moment to broaden your watchlist with 40 healthcare AI stocks

Even after the recent surge, 10x Genomics trades at about a 14% discount to one intrinsic value estimate, yet slightly above the average analyst target. This raises the question: is this a genuine buying opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 43.2% Overvalued

The most followed narrative pegs 10x Genomics' fair value at $20.14, which sits well below the recent $28.84 close and frames the current debate.

Adoption of new lower-cost consumables (like GEM-X Flex and Universal On Chip Multiplex) is increasing reaction volumes and enabling scale, positioning 10x Genomics to capture growing demand in single-cell and multiomic analysis driven by precision medicine, likely supporting long-term revenue and recurring, high-margin consumables sales.

Want to see how this consumables engine feeds into the fair value math? The narrative leans heavily on future revenue, margin recovery, and a premium earnings multiple.

Result: Fair Value of $20.14 (OVERVALUED)

However, there are still clear pressure points, including weaker academic and government funding and discounting on instruments that could weigh on revenue and margins.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: Cash Flows Tell a Different Story

The analyst consensus points to a fair value of $20.14, which implies 10x Genomics is overvalued at the recent $28.84 price. Yet our DCF model points the other way, with a future cash flow value of $33.45, suggesting the stock trades at a 13.8% discount. Which lens do you trust more for a business that is still unprofitable today?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out 10x Genomics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Torn between the upbeat recent returns and the more cautious fair value debate? Act sooner rather than later by weighing both sides with 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If 10x Genomics is already on your radar, do not stop there. Broaden your opportunity set with a few targeted stock ideas built from data driven screens.

• Target potential mispricings by scanning 44 high quality undervalued stocks that balance quality, earnings power, and pricing that may not fully reflect fundamentals.
• Strengthen your income watchlist by reviewing 8 dividend fortresses that pair higher yields with a focus on durability.
• Sleep easier at night by checking 70 resilient stocks with low risk scores designed to highlight companies with more resilient profiles and fewer red flags.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.